🚀 VC round data is live in beta, check it out!
Vistagen Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vistagen Therapeutics and similar public comparables like Nanogroup, Barinthus Biotherapeutics, Oncoinvent, Lexaria Bioscience and more.
Vistagen Therapeutics Overview
About Vistagen Therapeutics
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Founded
1998
HQ
Employees
57
Website
Sectors
Financials (LTM)
Market Cap
$22M
Vistagen Therapeutics Financials
Vistagen Therapeutics reported last 12-month revenue of $1M.
In the same LTM period, Vistagen Therapeutics generated had net loss of ($68M).
Revenue (LTM)
Vistagen Therapeutics P&L
In the most recent fiscal year, Vistagen Therapeutics reported revenue of $486K and EBITDA of ($55M).
Vistagen Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1M | XXX | $486K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($55M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (11386%) | XXX | XXX | XXX |
| EBIT Margin | (6515%) | XXX | (11517%) | XXX | XXX | XXX |
| Net Profit | ($68M) | XXX | ($51M) | XXX | XXX | XXX |
| Net Margin | (6302%) | XXX | (10580%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vistagen Therapeutics Stock Performance
Vistagen Therapeutics has current market cap of $22M.
Market Cap Evolution
Vistagen Therapeutics' stock price is $0.56.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $22M | 0.4% | XXX | XXX | XXX | $-1.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVistagen Therapeutics Valuation Multiples
Vistagen Therapeutics trades at (35.7x) EV/Revenue multiple, and 0.7x EV/EBITDA.
EV / Revenue (LTM)
Vistagen Therapeutics Financial Valuation Multiples
As of April 11, 2026, Vistagen Therapeutics has market cap of $22M.
Equity research analysts estimate Vistagen Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vistagen Therapeutics has a P/E ratio of (0.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $22M | XXX | $22M | XXX | XXX | XXX |
| EV (current) | ($38M) | XXX | ($38M) | XXX | XXX | XXX |
| EV/Revenue | (35.7x) | XXX | (78.8x) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.7x | XXX | XXX | XXX |
| P/E | (0.3x) | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vistagen Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vistagen Therapeutics Margins & Growth Rates
Vistagen Therapeutics' revenue in the last 12 month grew by 13%.
Vistagen Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
Vistagen Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 120% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (11386%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 12% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1604% | XXX | 3515% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4805% | XXX | 8103% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 11617% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vistagen Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nanogroup | XXX | XXX | XXX | XXX | XXX | XXX |
| Barinthus Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncoinvent | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexaria Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempest Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vistagen Therapeutics M&A Activity
Vistagen Therapeutics acquired XXX companies to date.
Last acquisition by Vistagen Therapeutics was on XXXXXXXX, XXXXX. Vistagen Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vistagen Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVistagen Therapeutics Investment Activity
Vistagen Therapeutics invested in XXX companies to date.
Vistagen Therapeutics made its latest investment on XXXXXXXX, XXXXX. Vistagen Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vistagen Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vistagen Therapeutics
| When was Vistagen Therapeutics founded? | Vistagen Therapeutics was founded in 1998. |
| Where is Vistagen Therapeutics headquartered? | Vistagen Therapeutics is headquartered in United States. |
| How many employees does Vistagen Therapeutics have? | As of today, Vistagen Therapeutics has over 57 employees. |
| Who is the CEO of Vistagen Therapeutics? | Vistagen Therapeutics' CEO is Shawn K. Singh. |
| Is Vistagen Therapeutics publicly listed? | Yes, Vistagen Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Vistagen Therapeutics? | Vistagen Therapeutics trades under VTGN ticker. |
| When did Vistagen Therapeutics go public? | Vistagen Therapeutics went public in 2009. |
| Who are competitors of Vistagen Therapeutics? | Vistagen Therapeutics main competitors are Nanogroup, Barinthus Biotherapeutics, Oncoinvent, Lexaria Bioscience. |
| What is the current market cap of Vistagen Therapeutics? | Vistagen Therapeutics' current market cap is $22M. |
| What is the current revenue of Vistagen Therapeutics? | Vistagen Therapeutics' last 12 months revenue is $1M. |
| What is the current revenue growth of Vistagen Therapeutics? | Vistagen Therapeutics revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Vistagen Therapeutics? | Current revenue multiple of Vistagen Therapeutics is (35.7x). |
| Is Vistagen Therapeutics profitable? | No, Vistagen Therapeutics is not profitable. |
| What is the current net income of Vistagen Therapeutics? | Vistagen Therapeutics' last 12 months net income is ($68M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.